Literature DB >> 19670416

Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test.

Jasmohan S Bajaj1, Kia Saeian, Christine M Schubert, Muhammad Hafeezullah, Jose Franco, Rajiv R Varma, Douglas P Gibson, Raymond G Hoffmann, R Todd Stravitz, Douglas M Heuman, Richard K Sterling, Mitchell Shiffman, Allyne Topaz, Sherry Boyett, Debulon Bell, Arun J Sanyal.   

Abstract

UNLABELLED: Patients with minimal hepatic encephalopathy (MHE) have impaired driving skills, but association of MHE with motor vehicle crashes is unclear. Standard psychometric tests (SPT) or inhibitory control test (ICT) can be used to diagnose MHE. The aim was to determine the association of MHE with crashes and traffic violations over the preceding year and on 1-year follow-up. Patients with cirrhosis were diagnosed with MHE by ICT (MHEICT) and SPT (MHESPT). Self and department-of-transportation (DOT)-reports were used to determine crashes and violations over the preceding year. Agreement between self and DOT-reports was analyzed. Patients then underwent 1-year follow-up for crash/violation occurrence. Crashes in those with/without MHEICT and MHESPT were compared. 167 patients with cirrhosis had DOT-reports, of which 120 also had self-reports. A significantly higher proportion of MHEICT patients with cirrhosis experienced crashes in the preceding year compared to those without MHE by self-report (17% vs 0.0%, P = 0.0004) and DOT-reports (17% vs 3%, P = 0.004, relative risk: 5.77). SPT did not differentiate between those with/without crashes. A significantly higher proportion of patients with crashes had MHEICT compared to MHESPT, both self-reported (100% vs 50%, P = 0.03) and DOT-reported (89% vs 44%, P = 0.01). There was excellent agreement between self and DOT-reports for crashes and violations (Kappa 0.90 and 0.80). 109 patients were followed prospectively. MHEICT patients had a significantly higher future crashes/violations compared to those without (22% vs 7%, P = 0.03) but MHESPT did not. MHEICT (Odds ratio: 4.51) and prior year crash/violation (Odds ratio: 2.96) were significantly associated with future crash/violation occurrence.
CONCLUSION: Patients with cirrhosis and MHEICT have a significantly higher crash rate over the preceding year and on prospective follow-up compared to patients without MHE. ICT, but not SPT performance is significantly associated with prior and future crashes and violations. There was an excellent agreement between self- and DOT-reports.

Entities:  

Mesh:

Year:  2009        PMID: 19670416      PMCID: PMC2757520          DOI: 10.1002/hep.23128

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  27 in total

1.  Inhibitory control test is a simple method to diagnose minimal hepatic encephalopathy and predict development of overt hepatic encephalopathy.

Authors:  Jasmohan S Bajaj; Kia Saeian; Matthew D Verber; Darrell Hischke; Raymond G Hoffmann; Jose Franco; Rajiv R Varma; Stephen M Rao
Journal:  Am J Gastroenterol       Date:  2007-01-11       Impact factor: 10.864

2.  Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations.

Authors:  Jasmohan S Bajaj; Muhammad Hafeezullah; Raymond G Hoffmann; Kia Saeian
Journal:  Am J Gastroenterol       Date:  2007-07-19       Impact factor: 10.864

3.  Doctors, drugs, and driving--tort liability for patient-caused accidents.

Authors:  George J Annas
Journal:  N Engl J Med       Date:  2008-07-31       Impact factor: 91.245

Review 4.  The role of reduced fitness to drive due to medical impairments in explaining crashes involving older drivers.

Authors:  Shawn C Marshall
Journal:  Traffic Inj Prev       Date:  2008-08       Impact factor: 1.491

Review 5.  Attention, memory, and cognitive function in hepatic encephalopathy.

Authors:  Karin Weissenborn; Kathrin Giewekemeyer; Susanne Heidenreich; Martin Bokemeyer; Georg Berding; Björn Ahl
Journal:  Metab Brain Dis       Date:  2005-12       Impact factor: 3.584

6.  Impairment of response inhibition precedes motor alteration in the early stage of liver cirrhosis: a behavioral and electrophysiological study.

Authors:  Sami Schiff; Antonino Vallesi; Daniela Mapelli; Raffaele Orsato; Andrea Pellegrini; Carlo Umiltà; Angelo Gatta; Piero Amodio
Journal:  Metab Brain Dis       Date:  2005-12       Impact factor: 3.584

7.  Task-induced fatigue and collisions in adult drivers with attention deficit hyperactivity disorder.

Authors:  Bryan Reimer; Lisa A D'Ambrosio; Joseph F Coughlin; Ronna Fried; Joseph Biederman
Journal:  Traffic Inj Prev       Date:  2007-09       Impact factor: 1.491

8.  Navigation skill impairment: Another dimension of the driving difficulties in minimal hepatic encephalopathy.

Authors:  Jasmohan S Bajaj; Muhammad Hafeezullah; Raymond G Hoffmann; Rajiv R Varma; Jose Franco; David G Binion; Thomas A Hammeke; Kia Saeian
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

9.  Deleterious effect of cirrhosis on outcomes after motor vehicle crashes using the nationwide inpatient sample.

Authors:  Jasmohan S Bajaj; Ashwin N Ananthakrishnan; Emily L McGinley; Raymond G Hoffmann; Karen J Brasel
Journal:  Am J Gastroenterol       Date:  2008-07-04       Impact factor: 10.864

10.  Patients with minimal hepatic encephalopathy have poor insight into their driving skills.

Authors:  Jasmohan S Bajaj; Kia Saeian; Muhammad Hafeezullah; Raymond G Hoffmann; Thomas A Hammeke
Journal:  Clin Gastroenterol Hepatol       Date:  2008-10       Impact factor: 11.382

View more
  81 in total

1.  Canadian regulations and legal ramifications for hepatic encephalopathy: a descriptive analysis.

Authors:  Henry H Nguyen; Mark G Swain; Philip Wong; Stephen E Congly
Journal:  CMAJ Open       Date:  2018-12-03

Review 2.  Advances in the evaluation and management of minimal hepatic encephalopathy.

Authors:  Jennifer Y Montgomery; Jasmohan S Bajaj
Journal:  Curr Gastroenterol Rep       Date:  2011-02

3.  Motor vehicle accidents: how should cirrhotic patients be managed?

Authors:  Takumi Kawaguchi; Eitaro Taniguchi; Michio Sata
Journal:  World J Gastroenterol       Date:  2012-06-07       Impact factor: 5.742

4.  An accurate, objective test for minimal hepatic encephalopathy may provide a medical basis to prevent driving while encephalopathic.

Authors:  Mitchell S Cappell; Navakanth Gorrepati
Journal:  Dig Dis Sci       Date:  2010-11       Impact factor: 3.199

5.  Persistence of cognitive impairment after resolution of overt hepatic encephalopathy.

Authors:  Jasmohan S Bajaj; Christine M Schubert; Douglas M Heuman; James B Wade; Douglas P Gibson; Allyne Topaz; Kia Saeian; Muhammad Hafeezullah; Debulon E Bell; Richard K Sterling; R Todd Stravitz; Velimir Luketic; Melanie B White; Arun J Sanyal
Journal:  Gastroenterology       Date:  2010-02-20       Impact factor: 22.682

Review 6.  Advances in psychometric tests for screening minimal hepatic encephalopathy: From paper-and-pencil to computer-aided assessment.

Authors:  Ming Luo; Ping Ma; Lei Li; Wu-Kui Cao
Journal:  Turk J Gastroenterol       Date:  2019-05       Impact factor: 1.852

7.  The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy.

Authors:  Jasmohan S Bajaj; Leroy R Thacker; Douglas M Heuman; Michael Fuchs; Richard K Sterling; Arun J Sanyal; Puneet Puri; Mohammad S Siddiqui; Richard T Stravitz; Iliana Bouneva; Velimir Luketic; Nicole Noble; Melanie B White; Pamela Monteith; Ariel Unser; James B Wade
Journal:  Hepatology       Date:  2013-05-23       Impact factor: 17.425

Review 8.  Disaccharides in the treatment of hepatic encephalopathy.

Authors:  Praveen Sharma; Barjesh Chander Sharma
Journal:  Metab Brain Dis       Date:  2013-03-02       Impact factor: 3.584

9.  Predicting Overt Hepatic Encephalopathy for the Population With Cirrhosis.

Authors:  Elliot B Tapper
Journal:  Hepatology       Date:  2019-05-10       Impact factor: 17.425

10.  Driving Performance Among Patients with Cirrhosis Who Drove to Their Outpatient Hepatology Clinic Appointments.

Authors:  Paul J Thuluvath; Anantha Nuthalapati; Jennifer Price; Anurag Maheshwari
Journal:  J Clin Exp Hepatol       Date:  2015-10-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.